Currently Viewing:
SGO Annual Meeting on Women's Cancer
Dr Martha Gaines: Turning Experience as Cancer Survivor into Patient Advocacy
April 20, 2018
Dr Sean C. Dowdy Discusses Improving Surgical Outcomes in Gynecologic Oncology
April 18, 2018
Dr William Cliby: Patient Factors and Surgery, Quality of Care For Ovarian Cancer
April 16, 2018
Dr Anna Beavis Highlights Importance of Addressing Gender Gaps in HPV Vaccination
April 15, 2018
Currently Reading
Dr Oliver Dorigo: Novel Therapies Being Researched by Stanford for Gynecologic Malignancies
April 13, 2018
Dr Sean C. Dowdy: Reducing Opioid Abuse in Patients Undergoing Surgery for Gynecologic Malignancies
April 04, 2018
Study Models ASCO Alternative Payment Model in Advanced Ovarian Cancer Care
March 27, 2018
Study Explores Mechanism Linking Statin to Reduced Tumor Size in Endometrial Cancer
March 26, 2018
Dr Oliver Dorigo on New, Innovative Therapies in Gynecologic Cancers
March 26, 2018
Dr William Cliby Explains Predictors of Patient Outcomes in Ovarian Cancer
March 26, 2018
Putting PARP Inhibitor Perspectives Into Practice in "Beyond the Guidelines" Session
March 26, 2018
Dr Anna Beavis Discusses Gender Differences in HPV Vaccination
March 25, 2018
Dr Victoria Bae-Jump on Obesity and Endometrial Cancer
March 25, 2018
Boys Don't Get HPV Vaccination Because Doctors Don't Recommend It, Study Finds
March 25, 2018
Deciding When to Use PARP Inhibitors, and Which One
March 25, 2018
Dr Scott Page: Diversity in Healthcare Improves Patient Outcomes
March 25, 2018
Clinical Trials Can Reduce Disparities in Advanced Ovarian Cancer, but Funding Is Needed, Researchers Say
March 25, 2018
Dr Martha Gaines Discusses the Importance of the Patient Voice
March 25, 2018

Dr Oliver Dorigo: Novel Therapies Being Researched by Stanford for Gynecologic Malignancies

Our division at Stanford is very interested in investigating innovative therapies and has a particular focus on immunotherapies, explained Oliver Dorigo, MD, PhD, associate professor, obstetrics and gynecology, Stanford University Medical Center.


Our division at Stanford is very interested in investigating innovative therapies and has a particular focus on immunotherapies, explained Oliver Dorigo, MD, PhD, associate professor, obstetrics and gynecology, Stanford University Medical Center.

Transcript

Are there any novel therapies currently being researched by your division for gynecologic malignancies?

Our division at Stanford in gynecologic oncology is very interested in pushing and investigating very innovative therapies. We have a particular focus on immunotherapies. Immunotherapies can be very diverse. Immune checkpoint inhibitors, as they have been approved, are still being investigated in clinical trials, in particular, in combination with chemotherapy or other immunostimulant drugs.

I’m very excited about cell therapies that allow us to use the body’s own white blood cells, or the patient’s own white blood cells, to potentially create antitumor effects. So, these white blood cells they’re taking out of the patients, they’re potentially genetically modified, so they recognize the tumor. They are then being reinfused, and hopefully recognize the tumor and have antitumor effects.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!